- Home
- AVNT vs MRUS Comparison
AVNT vs MRUS Comparison
Compare AVNT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNT | MRUS |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 5.1B |
| IPO Year | 1993 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AVNT | MRUS |
|---|---|---|
| Price | $30.87 | $96.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 17 |
| Target Price | $45.67 | ★ $94.94 |
| AVG Volume (30 Days) | 721.8K | ★ 1.4M |
| Earning Date | 11-05-2025 | 10-31-2025 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $3,246,100,000.00 | $56,606,000.00 |
| Revenue This Year | $2.24 | $56.08 |
| Revenue Next Year | $2.48 | N/A |
| P/E Ratio | $25.61 | ★ N/A |
| Revenue Growth | 1.03 | ★ 57.54 |
| 52 Week Low | $27.48 | $33.19 |
| 52 Week High | $49.23 | $96.94 |
Technical Indicators
Market Signals| Indicator | AVNT | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 74.48 |
| Support Level | $29.86 | $96.60 |
| Resistance Level | $31.83 | $96.83 |
| Average True Range (ATR) | 0.86 | 0.22 |
| MACD | 0.22 | -0.15 |
| Stochastic Oscillator | 73.08 | 97.92 |
Price Performance
Historical ComparisonAbout AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.